CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.07B, above the global median of $1.15B
- FinancialsAltman Z-Score 5.04: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
2.07BUSDvs all stocks (USD)
Revenue (TTM)
42.95MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.56xvs all stocks
52-Week Change
321.27%vs all stocks
Market Capitalization
2.07BUSDvs all stocks (USD)
Enterprise Value
1.45BUSDvs all stocks (USD)
Forward P/E
-13.54xvs Biotechnology peers
Price to Sales (TTM)
48.30xvs Biotechnology peers
Price to Book (MRQ)
3.97xvs Biotechnology peers
Enterprise to Revenue
33.70xvs Biotechnology peers
Enterprise to EBITDA
-10.35xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1188.46%vs Biotechnology peers
Return on Assets (TTM)
-16.41%vs Biotechnology peers
Return on Equity (TTM)
-32.62%vs Biotechnology peers
Revenue (TTM)
42.95MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4910USDUpdated Jul 19, 2026Quarterly Revenue Growth
-95.00%vs Biotechnology peers
Gross Profit (TTM)
-102.46MUSDvs all stocks (USD)
EBITDA (TTM)
-139.94MUSDvs all stocks (USD)
Net Income (TTM)
-130.01MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-95.04%vs Biotechnology peers
Operating Cash Flow (TTM)
-14.68MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-61.15MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
123.67MUSDFY2025 · Dec 31, 2025Operating Income
-54.21MUSDvs all stocks (USD)
Pre-tax Income
-39.72MUSDFY2025 · Dec 31, 2025Income Tax Expense
-1.10MUSDFY2025 · Dec 31, 2025Net Income
-38.63MUSDFY2025 · Dec 31, 2025EBIT
-54.21MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-47.40MUSDFY2025 · Dec 31, 2025Research & Development
141.50MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
36.38MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.94MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-38.63MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-29.05MUSDFY2025 · Dec 31, 2025Free Cash Flow
-33.75MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
134.84MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-38.63MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
8.36MUSDFY2025 · Dec 31, 2025Stock-based Compensation
18.86MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-11.43MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-13.71MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
7.49MUSDFY2025 · Dec 31, 2025Capital Expenditures
-4.70MUSDFY2025 · Dec 31, 2025Purchase of Investments
-376.68MUSDFY2025 · Dec 31, 2025Sale of Investments
279.54MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-101.83MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-357.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
23.89MUSDFY2025 · Dec 31, 2025Shares Outstanding
84.32MSharesUpdated Jul 19, 2026Float Shares
54.01MSharesUpdated Jul 19, 2026Shares Short
18.63MSharesUpdated Jul 19, 2026Short Ratio
11.61daysvs all stocks
Short % of Shares Outstanding
22.41%vs all stocks
% Held by Insiders
0.58%vs all stocks
% Held by Institutions
113.24%vs all stocks
Total Cash (MRQ)
666.22MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.89USDUpdated Jul 19, 2026Total Debt (MRQ)
39.06MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0748xvs Biotechnology peers
Current Ratio (MRQ)
9.54xvs Biotechnology peers
Book Value per Share (MRQ)
6.19USDUpdated Jul 19, 2026Total Assets
448.66MUSDvs all stocks (USD)
Total Current Assets
393.19MUSDFY2025 · Dec 31, 2025Total Liabilities
215.60MUSDFY2025 · Dec 31, 2025Total Non-current Assets
55.47MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
151.39MUSDFY2025 · Dec 31, 2025Total Current Liabilities
64.21MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
129.88MUSDFY2025 · Dec 31, 2025Other Short-term Investments
247.22MUSDFY2025 · Dec 31, 2025Accounts Payable
3.55MUSDFY2025 · Dec 31, 2025Short-term Debt
4.40MUSDFY2025 · Dec 31, 2025Deferred Revenue
29.57MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.58MUSDFY2025 · Dec 31, 2025Long-term Debt
34.79MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-477.21MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
233.06MUSDvs all stocks (USD)
52-Week Low
4.12USDUpdated Jul 19, 202652-Week High
25.77USDUpdated Jul 19, 202652-Week Change
321.27%vs all stocks
Beta
1.56xvs all stocks
50-Day MA
20.15USDUpdated Jul 19, 2026200-Day MA
17.46USDUpdated Jul 19, 2026Avg 10-Day Volume
1.30MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.55MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.48USDUpdated Jul 19, 2026Other Income / Expense
1.54MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 48.30Revenue Growth YoY: -0.95
Financial Health
Altman Z-Score 5.04: safe zoneNotable
Altman Z-Score: 5.04
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.07B, above the global median of $1.15BNotable
Market cap (USD): 2,074,814,506Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aurinia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Jiangsu Xinquan Automotive Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Super Telecom Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Shengjian Technology Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated